Summary of the Conference Call for 康宁杰瑞 Company Overview - **Company**: 康宁杰瑞 - **Core Products**: - KN026 (HER2 bispecific antibody) - KN003 (HER2 bispecific ADC) - KN016 (TROP2/HER3 bispecific ADC) - KN033 (first IO+ADC subcutaneous formulation) - Early pipeline products: KN022, KN027, KN021 Key Points and Arguments Product Development and Clinical Trials - **KN026**: NDA for second-line gastric cancer accepted, expected approval in H1 2026; overall survival (OS) data nearing 20 months, significantly better than existing therapies [2][4] - **KN003**: Phase III data for second-line breast cancer expected in 2026; ORR close to 70% in colorectal cancer and 63.8% in platinum-resistant ovarian cancer, with safety profile superior to T-DM1 [2][4] - **KN016**: Focused on lung and breast cancer, Phase III for triple-negative breast cancer (TNBC) initiated, with HR+ breast cancer data expected in 2026 [2][4] - **KN033**: Progressing well, targeting second-line cervical/endometrial cancer, EOP2 submission expected in 2026 [2][4] - **Early Pipeline**: KN022, KN027, and KN021 in dose escalation, with multiple POC data updates anticipated in 2026 [2][4] Financial Performance - **2025 Financials**: Total revenue of 566 million CNY, with product license revenue at 73%; R&D expenses reached 572 million CNY, a five-year high; cash reserves at 1.35 billion CNY; loss of approximately 100 million CNY due to increased clinical R&D costs [4][27] - **2026 Outlook**: Key year with expectations for the second product launch and third product submission, alongside multiple overseas IND applications [2][4] Strategic Partnerships and Market Position - **Overseas Strategy**: Shiyao responsible for domestic sales, while the company retains overseas rights; plans to leverage strong Phase III data for potential business development or direct EU applications [3][21] - **Sales Expectations**: Peak sales for KN026 and KN003 could reach 5 billion CNY, with production capacity ensuring supply for at least 1.5 million units of KN026 [19][27] Regulatory and Certification Achievements - **Regulatory Milestones**: Six certifications from domestic and international authorities in 2025, including multiple BTD and orphan drug designations for KN003 [4][27] Future Milestones - **2026 Milestones**: - H1: Launch of KN026 for breast cancer, new data for gastric cancer, and initiation of KN003 colorectal cancer trials [17][27] - H2: Submission of KN026 for breast cancer, data readout for KN003, and initiation of KN016 trials for non-small cell lung cancer [17][27] Clinical Data and Competitive Landscape - **KN026 vs. Competitors**: Demonstrated superior efficacy in gastric cancer compared to T-DXd and T-DM1, with potential to set new standards in treatment [7][12] - **KN003 in Ovarian Cancer**: ORR of 63.8% in platinum-resistant ovarian cancer, with significant safety advantages over competitors [11][12] Product Synergy - **Complementary Product Strategy**: KN026 and KN003 designed to cover the full lifecycle of HER2-positive breast and gastric cancers, enhancing the company's growth potential [13][19] Research and Development Focus - **Innovative Pipeline**: Focus on dual-target ADCs and novel payloads, with ongoing exploration of new mechanisms and clinical applications [26][27] Additional Important Information - **Market Dynamics**: The company is preparing for competitive pressures from established therapies and generics, emphasizing the need for strong clinical data to support market entry [21][27] - **Long-term Vision**: Commitment to addressing unmet clinical needs while ensuring shareholder returns through innovative product development and strategic partnerships [27]

Investment Rating - The report provides a positive outlook for CSPC Pharmaceutical Group, indicating a clear roadmap for internationalization and significant revenue growth expected from completed business development transactions by 2026 [5][6]. Core Insights - CSPC is projected to convert its completed business development transactions into recurring revenue by 2026, supported by major research milestones and successful overseas development progress [6]. - The company has secured approximately $10.2 billion in upfront and milestone payments from significant partnerships with AstraZeneca and Madrigal, which are expected to enhance profitability from 2025 to 2027 [5][6]. - Key products such as KN026 and SYS6010 are anticipated to drive domestic business recovery and accelerate growth post-2027 [7]. Summary by Sections Business Development and Revenue - CSPC's completed business development transactions are expected to yield around $9 billion in free cash flow from milestone payments by 2030, with AstraZeneca's recent $1.2 billion non-refundable upfront payment being a significant contributor [6]. - The company has established eight innovative R&D platforms, transitioning from a raw material producer to a complex generics and innovative drug enterprise, achieving a compound annual growth rate of 3.1% in profitability from 2019 to 2023 [10]. Market Position and Financials - As of February 2, 2026, CSPC's stock price was HKD 9.15, with a market capitalization of $13.54 billion [13]. - The company ranks among the top ten in the Chinese pharmaceutical industry by drug revenue, with a significant portion of its income derived from the Asian market [11]. Catalysts for Growth - Key catalysts include the progress of overseas R&D projects, particularly the core product EGFR ADC, and the clinical development plans of major partners like AstraZeneca [8]. - The anticipated launch of innovative drugs and the entry of early-stage products into clinical phases are expected to validate the company's R&D capabilities [8].

Core Viewpoint - Dongwu Securities maintains a "Buy" rating for Corning Jereh Pharmaceutical-B (09966), anticipating multiple ADC pipelines to complete preclinical development by 2025, leading to adjustments in R&D expense forecasts and net profit estimates for 2025-2027 [1] Group 1: Pipeline Developments - The company has submitted a listing application for KN026, a HER2 bispecific monoclonal antibody, which is expected to receive approval by the end of 2026 or in 2027 [1] - JSKN003, the company's first ADC pipeline, is expected to submit a domestic listing application for HER2-positive breast cancer in 2026, with promising efficacy data presented at the 2025 ESMO conference for ovarian and colorectal cancers [2] Group 2: Clinical Progress and Efficacy Data - For JSKN003, the objective response rate (ORR) for platinum-resistant ovarian cancer patients was 32.0%, with a disease control rate (DCR) of 72.0%, and a median progression-free survival (PFS) of 4.1 months [2] - In colorectal cancer patients, JSKN003 achieved an ORR of 71.0%, a DCR of 100%, a median duration of response (DoR) of 9.89 months, and a median PFS of 11.04 months [2] Group 3: R&D Platform and Future Prospects - The company's self-developed platform continues to yield new pipelines, with the PD-L1/ITGB6/8 multifunctional ADC JSKN022 starting Phase I clinical trials in October 2025, and the PD-L1/VEGFR2 dual-target ADC JSKN027 having received IND approval in December 2025, with Phase I trials expected in 2026 [3]

Core Viewpoint - Dongwu Securities maintains a "Buy" rating for Kangning Jereh Pharmaceutical-B (09966), anticipating multiple ADC pipelines to complete preclinical development by 2025, leading to adjustments in R&D expense forecasts and net profit estimates for 2025-2027 [1] Group 1: Financial Projections - The forecast for net profit attributable to the parent company is adjusted to -115 million yuan for 2025 and -97 million yuan for 2026, down from 14 million yuan and 63 million yuan respectively; a new forecast for 2027 is set at -26 million yuan [1] - The company is expected to gradually reduce losses as products like KN026 are anticipated to be launched domestically, with JSKN003 also nearing its application for market approval [1] Group 2: Product Pipeline Developments - KN026, a HER2 bispecific monoclonal antibody, has had its application for marketing approval accepted by NMPA, with expectations for approval by the end of 2026 or in 2027; the domestic rights have been granted to CSPC Pharmaceutical Group, while the company retains exclusive production rights [1] - JSKN003, the company's first ADC pipeline, is expected to submit a domestic application for HER2-positive breast cancer in 2026, with promising efficacy data presented at the 2025 ESMO conference for ovarian and colorectal cancers [2] Group 3: Research and Development Advancements - The company's self-developed platform continues to yield new pipelines, with the PD-L1/ITGB6/8 multifunctional ADC JSKN022 showing superior internalization efficiency and cytotoxic activity, having initiated Phase I clinical trials in October 2025 [3] - The PD-L1/VEGFR2 bispecific ADC JSKN027 has integrated multiple mechanisms and has received acceptance for its IND application, with Phase I clinical trials expected to commence in 2026 [3] - Additional ADCs, such as EGFR/HER3 bispecific dual-load ADC JSKN021, are anticipated to enter clinical development stages [3]

Core Insights - The company has submitted a listing application for KN026, a HER2 dual-target monoclonal antibody, which is expected to be approved for gastric cancer treatment by the end of 2026 or in 2027 [1] - The company has granted domestic rights for KN026 to CSPC Pharmaceutical Group, which will handle commercialization, while the company retains exclusive production rights [1] - The first ADC pipeline, JSKN003, is progressing rapidly, with a domestic listing application expected in 2026 for its indication in HER2-positive breast cancer [1] - JSKN003 has shown promising efficacy data in ovarian and colorectal cancer, with an objective response rate (ORR) of 32.0% and a disease control rate (DCR) of 72.0% in platinum-resistant ovarian cancer patients [1] - The company’s self-developed platform continues to produce new ADC molecules, with JSKN022 and JSKN027 entering clinical trials in 2025 [2] - Revenue forecasts for 2025-2026 are maintained at 414 million and 471 million yuan, with an additional forecast of 563 million yuan for 2027 [2] Financial Projections - The company has adjusted its R&D expense forecasts, leading to a downward revision of net profit estimates for 2025 and 2026 to -115 million and -97 million yuan, respectively [3] - The net profit forecast for 2027 is also revised to -26 million yuan [3] - Despite the losses, the company is expected to gradually reduce its losses as KN026 approaches market entry and JSKN003 is set to apply for listing [3] - The company maintains a "buy" rating based on the positive development cycle of its R&D capabilities and the upcoming clinical stages of its pipeline [3]

Macro Strategy - The report highlights the investment value of the Guangfa CSI Media ETF (512980.SH), which is closely tracking the CSI Media Index (399971.SZ) and has a management fee of 0.5% per year and a custody fee of 0.1% per year [10] - As of January 16, 2026, the ETF has a circulation scale of 10.759 billion yuan, leading in scale and liquidity, with an annualized return of 29.47% and a volatility ratio of 0.89, indicating reasonable risk control [10] - The underlying index focuses on AI applications, with a high weight of GEO concept stocks, including major companies like BlueFocus and Rock Mountain Technology, which account for 31.43% of the index [10] - The report notes that the media sector is experiencing a bull market driven by AI technology transformation and the assetization of data elements, contrasting with the previous bull market driven by mobile internet traffic [10] Company Analysis Kangning Jereh Pharmaceutical-B (09966.HK) - The company is expected to have total revenues of 414 million yuan and 471 million yuan in 2025 and 2026, respectively, with a new forecast for 2027 at 563 million yuan [6] - The net profit forecast for 2025 and 2026 has been adjusted down to -115 million yuan and -97 million yuan, respectively, due to increased R&D expenses [6] - The company maintains a "Buy" rating as it anticipates a gradual reduction in losses with the upcoming domestic launch of product KN026 and the submission of JSKN003 for listing [6] Fuan Energy (002911) - The company reported a net profit of 1 billion yuan for 2025, a year-on-year increase of 17.3%, driven by strong growth in its energy and chemical business [17] - The forecast for net profit for 2025-2027 has been raised to 1 billion, 1.07 billion, and 1.12 billion yuan, respectively, reflecting a growth of 17.3%, 7.0%, and 4.4% [17] - The company maintains a "Buy" rating, supported by a stable natural gas business and diversified growth strategies [17] Huace Testing (300012) - The company expects a net profit of 1.01-1.02 billion yuan for 2025, with a growth rate of 10%-11%, and a strong performance in Q4 with a net profit increase of 15%-20% [18] - The report emphasizes the company's strategic focus on traditional markets and emerging sectors, which is expected to drive growth [19] - The company maintains an "Overweight" rating, with adjusted net profit forecasts for 2025-2027 at 1.02 billion, 1.16 billion, and 1.29 billion yuan [19] Tianfu Communication (300394) - The company forecasts a net profit of 1.88-2.15 billion yuan for 2025, representing a year-on-year increase of 40%-60% [20] - The growth is attributed to the acceleration of the AI industry and global data center construction, which has driven demand for high-speed optical devices [20] - The company is positioned to benefit from the upcoming commercial launch of its 1.6T optical engine products [20]

Group 1: Company Overview - The report focuses on 康宁杰瑞生物-B (9966.HK), which specializes in the development, production, and commercialization of innovative biopharmaceuticals in the oncology field, leveraging various core technology platforms [4][6] - The company has developed a differentiated pipeline that includes single-domain antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs), showcasing international competitiveness [4][5] Group 2: Product Pipeline and Commercialization - The commercialization of 安尼妥单抗 injection is imminent, targeting 2L+HER2+GC treatment and providing better clinical options for 1L/newly diagnosed HER2+ breast cancer patients [4][5] - The first listing application for 安尼妥单抗 for HER2+ gastric cancer has been accepted by NMPA, with expectations for approval within 2026, marking the beginning of a commercialization phase [4][5] - Multiple ongoing clinical trials for various indications, including 1L HER2+ breast cancer and HER2+ gastric cancer, indicate significant potential for blockbuster products [4][5] Group 3: Financial Projections - Revenue forecasts for 康宁杰瑞 are projected at 432 million, 484 million, and 596 million yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of -32.5%, 12.1%, and 23.0% [6] - The current price-to-sales (PS) ratios are estimated at 20.6x, 18.4x, and 14.9x for the respective years, indicating substantial upside potential due to effective drug commercialization and clinical data disclosures [6] Group 4: Industry Overview - The report highlights a positive macroeconomic environment for the non-ferrous metals industry, with significant price increases in metal commodities driven by supply constraints and favorable economic indicators [7][10] - The U.S. GDP for Q3 exceeded expectations, with a year-on-year growth rate of 4.3%, supporting consumer spending despite inflation and employment concerns [7][8] - The industrial added value for large-scale industries in China is expected to grow by 5.9% in 2025, indicating a robust manufacturing sector [9]

Core Viewpoint - In 2025, under the new "dual circulation" development pattern, China's capital market is undergoing a profound transformation, with the innovative drug sector emerging as a standout performer, marked by significant capital investment and a shift towards "hard technology" [1][3]. Industry Overview - The innovative drug sector has entered a clear structural bull market in 2025, driven by valuation recovery, policy support, and the trend of business development (BD) overseas, leading to a systematic reconstruction of the valuation framework [3]. - The investment logic in innovative drugs has shifted from a narrative focused on "stories and pipelines" to a deeper pricing based on "commercialization capability" and "sustained innovation momentum" [3]. - The competition in the future will focus on "platform-based innovation capability" rather than betting on single-target "probability games" [4]. Company Performance - 康宁杰瑞 (Cangning Jierei) achieved a remarkable stock price increase of 220.57% in 2025, becoming a leader among mid-to-large unprofitable biotech companies, and was awarded the "Annual Innovation Award" by 格隆汇 (Gelonghui) for its innovative model [1][5]. - The company successfully transitioned from early product development to focusing on the dual antibody/ADC golden track, marking a fundamental shift from "single product-driven" to "technology platform-driven" [7]. - Financially, 康宁杰瑞 reported a revenue of 319 million yuan in the first half of 2025, an 84% year-on-year increase, and a net profit of 21.58 million yuan, maintaining positive profitability [9]. Future Outlook - In 2026, 康宁杰瑞 is expected to enter a critical period for innovation results and value validation, with several milestone events and clinical data readouts acting as clear catalysts [12]. - Key products include KN026, JSKN003, and JSKN016, with anticipated regulatory approvals and clinical data expected to further solidify the company's position in the market [12][13]. - The capital market's recognition of 康宁杰瑞 is deepening, with multiple institutions raising ratings and target prices, indicating a clear long-term growth potential [13]. Conclusion - 康宁杰瑞's journey in 2025 reflects a broader transformation in the Chinese innovative drug landscape, emphasizing the importance of systematic platform capabilities over single blockbuster products [16][17]. - As the industry transitions from beta-driven benefits to alpha-driven differentiation, companies like 康宁杰瑞, with independent platforms and clear clinical strategies, are poised to become market leaders and define the next generation of treatment standards [16][18].

Summary of Corning Jereh Conference Call Company Overview - **Company**: Corning Jereh - **Key Products**: KN026, GSK003, KN035, GSKN016, GSKN027, GSKN0,333, and others - **Industry**: Oncology, specifically focusing on Antibody-Drug Conjugates (ADCs) Core Insights and Arguments - **KN026 Approval and Market Potential**: Expected approval in July 2026 for second-line and above HER2-positive gastric cancer, with peak sales anticipated to exceed 3 billion RMB [2][3] - **GSK003 Development**: A HER2 bispecific ADC using glycosylation site-specific conjugation technology, showing better efficacy and safety than existing single-target ADCs like TDM1. Expected to report second-line HER2-positive breast cancer data in 2026, with peak sales projected over 2.5 billion RMB [2][3] - **Technological Platforms**: Corning Jereh has two key platforms: glycosylation site-specific conjugation, which is more efficient than Synaffix, and a subcutaneous administration platform that enhances patient compliance [6][8] - **ADC Market Growth**: The ADC market has seen rapid growth, with over 10 billion USD in business development transactions globally last year, and total sales exceeding 12 billion USD, a 36% year-on-year increase [7][8] Clinical Data and Efficacy - **KN026 Clinical Performance**: In trials for HER2-positive gastric cancer, KN026 demonstrated mPFS and MOS superior to existing therapies, with an HR value below 0.3, indicating a significant reduction in disease progression and mortality risk [10][11] - **GSK003 in Ovarian Cancer**: Showed high ORR in platinum-resistant ovarian cancer, with low adverse reaction rates, indicating its potential as a significant treatment option [12] - **GSKN016 Development**: A dual-target ADC that is currently in the pipeline, expected to show promising safety and efficacy data in upcoming trials [15] Financial Outlook and Investment Recommendations - **Revenue Projections**: KN026's domestic sales peak is expected to exceed 3 billion RMB, while GSK003 is projected to reach 2.6 billion RMB. The company achieved profitability in 2024, primarily due to licensing fees from GSKN003 and sales of KN035 [6][19] - **Investment Rating**: The target price is set at 14.3 HKD, with a buy rating reflecting a 27% upside potential from the current closing price [19] Additional Noteworthy Points - **Pipeline Innovations**: The company is developing several innovative dual antibodies and combination formulations, which are at various clinical stages and may capture significant market share [8][9] - **Regulatory Milestones**: Key regulatory events are anticipated in 2026, including the approval of KN026 and GSK003, which could significantly enhance market potential [9][16] - **Emerging Products**: Other products like GSKN0,333 and GSKN027 are also in development, focusing on enhancing treatment efficacy and patient compliance [14][18]

Group 1 - The company is a pioneer in antibody technology in China, focusing on the research, production, and commercialization of innovative biopharmaceuticals for oncology, with a core technology platform that includes self-developed bispecific antibodies and ADC technology [2] - The global first PD-L1 subcutaneous injection KN035 was approved for market in November 2021, with expected sales and royalties of 130 million, 128 million, and 125 million yuan for 2025, 2026, and 2027 respectively [2] - The self-developed HER2 bispecific antibody KN026 has shown strong positive efficacy in treating 2L+ HER2-positive gastric cancer, with its application for market approval expected to be accepted by NMPA in September 2025, and anticipated approval in the second half of 2026 [2] Group 2 - JSKN003, a self-developed HER2 bispecific antibody ADC, is advancing in clinical trials for multiple indications in China, showing superior efficacy and safety compared to Enhertu, with data readout expected in 2027 [3] - The company plans to submit an NDA for 2L HER2-positive breast cancer in 2026 and will initiate a Phase III trial for HER2-positive metastatic colorectal cancer in October 2025, with projected sales of 0.05 million, 0.57 million, and 1.08 million yuan for 2027, 2028, and 2029 respectively [3] Group 3 - The company has established a diversified bispecific antibody ADC product matrix through its proprietary glycosylation site-specific conjugation technology platform and differentiated target layout strategy [4] - JSKN016 is the world's first TROP2/HER3 bispecific antibody ADC, currently enrolling over 400 patients for indications in lung and breast cancer, indicating a broad market potential [4] - JSKN022, a first-in-class targeted PD-L1/ITGB6 bispecific antibody ADC, initiated its first patient dosing in October, while JSKN027, which has a triple mechanism of action, is expected to file for IND soon [4]